Frailty
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
City TherapeuticsMA - Cambridge
1 programTriage Assessment and NEWS-score as Risk Predictor in Older Frailty Adults in the EDN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
LongeveronAllogeneic Human Mesenchymal Stem Cells
City TherapeuticsTriage Assessment and NEWS-score as Risk Predictor in Older Frailty Adults in the ED
Clinical Trials (2)
Total enrollment: 65 patients across 2 trials
AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery
Start: Mar 2014Est. completion: Oct 202065 patients
Phase 1/2Completed
NCT03783234City TherapeuticsTriage Assessment and NEWS-score as Risk Predictor in Older Frailty Adults in the ED
Triage Assessment and NEWS-score as Risk Predictor in Older Frailty Adults in the ED
Start: Dec 2018Est. completion: Oct 2020
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space